Condition: Brain Tumor, Pediatric · Medulloblastoma, Childhood · Embryonal Tumor · Sponsor: Bambino Gesù Hospital and Research Institute
The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory malignant central nervous system (CNS) tumors. In order to improve the safety of the approach, the suicide gene inducible Caspase 9 (iC9) has been included.
This description comes directly from the study's public registry record.
Francesca Del Bufalo, MD · 00396859 · francesca.delbufalo@opbg.net
Angela Mastronuzzi, MD, PhD · 00396859 · angela.mastronuzzi@opbg.net
Always discuss trial participation with your own doctor first.
| Ospedale Pediatrico Bambino Gesù | Roma, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05298995